CLX Cash & equivalents
Cash & equivalents at Clorox fell to $167M in fiscal 2025, the lowest in the 5 years reported, from $202M in 2024.
Cash and cash equivalents at year end, as filed.
SOURCE: us-gaap:CashAndCashEquivalentsAtCarryingValue · EDGAR CompanyFacts · CIK 21076 · EDGAR ↗ · FY2021–FY2025 · ANNUAL
FY2025$167M
FY2024 $202M
HIGH$367M FY2023
LOW$167M FY2025
History AS FILED · DERIVATION SHOWN WHERE DERIVED
| Fiscal year | Cash & equivalents | Change |
|---|---|---|
| FY2025 | $167M | $-35M |
| FY2024 | $202M | $-165M |
| FY2023 | $367M | +$184M |
| FY2022 | $183M | $-136M |
| FY2021 | $319M | — |
More SAME DATA, OTHER VIEWS
Cash & equivalents across coverage → · CLX company view →
Revenue · Net income · Operating cash flow · Free cash flow · Capital expenditure · Total assets · Shareholders' equity · Total debt · Return on equity · Days sales outstanding
Not investment advice. Every figure on this page is an XBRL fact from the issuer's own SEC filings or an arithmetic over such facts with the method shown. No forecast is made; no posture is expressed.